PlainPharmaWatch

CMS Open Payments · Program Year 2024

Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. reported $11,411,406.41 across General Payments, Research, and Ownership to 4,194 physicians and teaching hospitals across 5,015 transactions.

See the rankings → How this is sourced
$11.4M
All-tracks total
5,015
Transactions
4,194
Recipients
+$859.5K
General Payments vs PY2023

Ocular Therapeutix, Inc. reported $11,411,406.41 across all CMS Open Payments tracks (General + Research + Ownership) to 4,194 physicians and teaching hospitals in Program Year 2024 - ranking #153 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $1,815,978.76, averaging $2.7K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer ocular-therapeutix-inc Ocular Therapeutix, Inc.

$11.4M · #153/1,925 · 0.1% industry · PY2024

  • TOT $11.4M
  • RANK #153
  • SHARE 0.1%
  • TXN 5,015
  • RCP 4,194
  • CAT 6
  • GEN $1.8M
  • ΔGEN +$859.5K
  • TOP1 16.3%
  • PY 2024

Volume peers

Nearest volume peer: IBSA Institut Biochimique SA ($11.4M)

Iovance Biotherapeutics, Inc.$11.5MOcular Therapeutix, Inc. (th…$11.4MIBSA Institut Biochimique SA$11.4MTris Pharma Inc$11.4MAbiomed$11.3M
All-tracks payment totals near Ocular Therapeutix, Inc. (CMS Open Payments PY2024)

Ocular Therapeutix, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Ocular Therapeutix, Inc.'s CMS-reported General Payments increased by $859.5K (+89.9%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: OCULAR THERAPEUTIX, INC.PY2023: OCULAR THERAPEUTIX, INC.PY2024: Ocular Therapeutix, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$956.5KPY2024$1.8M
PY2023
$956,514.97
PY2024
$1,815,978.76

What the Data Shows for Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. ranks #153 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.1% slice of all industry payments reported nationwide for the year. The underlying total is $11,411,406.41 across 5,015 transactions to 4,194 physicians and teaching hospitals - $2.3K per transaction and $2.7K per recipient on average.

Of the 6 general-payment categories charted below, "Consulting Fee" is the largest at $1.5M across 342 transactions, 84.3% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Consulting Fee" leads Ocular Therapeutix, Inc.'s 6-category general-payment breakdown at $1.5M, 84.3% of the reported total.

Ocular Therapeutix, Inc. reports 6 general-payment categories - the top three are Consulting Fee (84.3%), Food and Beverage (8.1%), and Compensation for Faculty or Speaker (Medical Education) (3.9%). The remaining 3 categories make up 3.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Ocular Therapeutix, Inc. divides its payments

Top payment categories by total reported dollar volume

1. Consulting Fee$1.5M2. Food and Beverage$147.1K3. Compensation for Faculty …$71.5K4. Honoraria$37.8K5. Travel and Lodging$22.9K6. Long-Term Medical Supply …$6.6K
Payment Type Amount Transactions
Consulting Fee $1.5M 342
Food and Beverage $147.1K 3,726
Compensation for Faculty or Speaker (Medical Education) $71.5K 25
Honoraria $37.8K 25
Travel and Lodging $22.9K 44
Long-Term Medical Supply or Device Loan $6.6K 32

Recipient Concentration in General Payments

The five largest recipient relationships account for $961,481.67 (52.9%) of $1,815,978.76 in this company's General Payments records across 1,826 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Ocular Therapeutix, Inc.

The five named recipients with the highest reported General Payments from this company

Richard Lindstrom$296.3KBaruch Kuppermann$242.6KDarius Moshfeghi$193.3KAndrew Moshfeghi$131.1KDilsher Dhoot$98.3K
  1. 1

    Richard Lindstrom

    $296,312.39 across 2 reported transactions

  2. 2

    Baruch Kuppermann

    $242,559.63 across 24 reported transactions

  3. 3

    Darius Moshfeghi

    $193,271.37 across 25 reported transactions

  4. 4

    Andrew Moshfeghi

    $131,064.37 across 16 reported transactions

  5. 5

    Dilsher Dhoot

    $98,273.91 across 57 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Ocular Therapeutix, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ocular Therapeutix, Inc..

Guard Medical Inc.

HHI 712

Central Indiana URS Consumables, LLC

HHI 714

Oticon Medical, LLC

HHI 706

Brainlab, Inc.

HHI 717

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Ocular Therapeutix, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Ocular Therapeutix, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.